Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SFXN3 is Associated with Poor Clinical Outcomes and Sensitivity to the Hypomethylating Therapy in Non-M3 Acute Myeloid Leukemia Patients.

Current gene therapy - 1 Jan 2023

Dong Yuxuan, Jin Fengbo, Wang Jing, Li Qingsheng, Huang Zhenqi, Xia Leiming, Yang Mingzhen

Abstract excerpt

BACKGROUND: DNA hypermethylation plays a critical role in the occurrence and progression of acute myeloid leukemia (AML). The mitochondrial serine transporter, SFXN3, is vital for onecarbon metabolism and DNA methylation. However, the impact of SFXN3 on the occurrence and progression of AML has not been reported yet. OBJECTIVE: In this study, we hypothesized that SFXN3 indicates a poor prognosis and suggested...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cation Transport Proteins
Share to DNA Methylation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Leukemic

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 37491851
DOI: 10.2174/1566523223666230724121515
PMCID: PMC10614111

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SFXN3 is Associated with Poor Clinical Outcomes and Sensitivity to the Hypomethylating Therapy in Non-M3 Acute Myeloid Leukemia Patients.PMID 37491851Read ↗

SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemiaSemantic proximity Read ↗

[Clinical features and survival analysis in non-M(3) acute myeloid leukemia patients with ASXL1 gene mutation].Semantic proximity Read ↗

Aberrant MNX1 expression associated with t(7;12)(q36;p13) pediatric acute myeloid leukemia induces the disease through altering histone methylationSemantic proximity Read ↗

Aberrant MNX1 Expression Associated with t(7;12)(q36;p13) Pediatric Acute Myeloid Leukemia Induces the Disease Through Altering Histone MethylationSemantic proximity Read ↗

SASH3 is an unfavorable prognostic immune biomarker in patients with acute myeloid leukemia(AML).Semantic proximity Read ↗

Prognostic significance of Spinster homolog gene family in acute myeloid leukemiaSemantic proximity Read ↗

Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia.Semantic proximity Read ↗

NSUN2-mediated cytosine-5 methylation of FSP1 protects acute myeloid leukemia cells from ferroptosisSemantic proximity Read ↗

Identification of Aberrantly Methylated and Silenced Genes in Acute Myeloid Leukemia by Combined Methylation/expression AnalysisSemantic proximity Read ↗

Identification and validation of SRY-box containing gene family member SOX30 methylation as a prognostic and predictive biomarker in myeloid malignanciesSemantic proximity Read ↗

NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia.Semantic proximity Read ↗

CTNNA1 hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.